|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
VEGF mRNA and protein expression was higher in the OIR and OIR control groups, compared with the normoxia and OIR‑treated groups.
|
30664207 |
2019 |
|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Here, however, we show by cell-specific depletion of Vhl in a mouse model of retinal ischemia (oxygen-induced retinopathy, OIR) that myeloid-derived HIFs promote VEGF and bFGF expression and enhance vascular regeneration in association with improved density and organization of the astrocytic network.
|
31583505 |
2019 |
|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Similarly, NPDR (SMD: 0.51, 95% CI: 0.22-0.80) and PDR (SMD: 1.32, 95% CI: 0.79-1.85) patients had higher serum VEGF levels compared with NDR patients, but the difference was not significant in plasma samples (SMD: 0.24, 95% CI: -0.47-0.95; SMD: 0.37, 95% CI: -0.30-1.05).
|
31019585 |
2019 |
|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
To examine the three-dimensional morphology and vascular endothelial growth factor (VEGF) expression of skin microvasculature in patients with type 2 diabetes in relation to neuropathy, retinopathy and nephropathy.
|
30719863 |
2019 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor (VEGF) is an important regulator of angiogenesis and has been investigated as a candidate gene in a number of conditions, including diabetes and its microvascular complications (e.g., retinopathy and nephropathy).
|
30579324 |
2019 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor A (VEGFA) is involved in the pathogenesis of vasoproliferative retinal diseases, such as exudative age-related macular degeneration (AMD).
|
30825671 |
2019 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The results suggest that the protective effect of TXF against cataract and retinopathy may be due to the anti-oxidative potential of TXF and its inhibiting effect on VEGF, ERK1/2, p38MAPK and aldose reductase.
|
31656158 |
2019 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Melatonin attenuated retinal neovascularization and neuroglial dysfunction by inhibition of HIF-1α-VEGF pathway in oxygen-induced retinopathy mice.
|
29411894 |
2018 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In this study, we addressed the potential relationship between prominin-1 (prom1) and vascular endothelial growth factor (VEGFA) in diabetes-induced retinopathy.
|
29076766 |
2018 |
|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Moreover, the expressions of HB-EGF and VEGF were increased after laser-induced CNV and oxygen-induced retinopathy, and their expression sites were located around the neovascular areas.
|
29191924 |
2018 |
|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
For the investigation of sevoflurane's effect on angiogenesis, the angiogenesis and VEGF expression in the retina were measured after administering sevoflurane in an oxygen-induced retinopathy mice model.
|
29464332 |
2018 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Using RNA interference for targeted inhibition of VEGF isoforms in conjunction with IGF-I may be preferable for suppression of HREC overgrowth in vasoproliferative retinopathies such as ROP.
|
30093937 |
2018 |
|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Our data show that myeloid-derived cells contribute to pathological neovascularization in oxygen-induced retinopathy through activation of VEGF-A expression in Müller cells.
|
29042140 |
2018 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
VEGF as a Trophic Factor for Müller Glia in Hypoxic Retinal Diseases.
|
29721978 |
2018 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
IR may be used as a model of ischemic retinopathy that includes VEGF-dependent vascular permeability and neurodegeneration.
|
29681725 |
2018 |
|
Retinal Diseases
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
Potential role of the methylation of VEGF gene promoter in response to hypoxia in oxygen-induced retinopathy: beneficial effect of the absence of AQP4.
|
28940930 |
2018 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
This study tested the hypothesis that endothelial cell-specific knockdown of VEGF receptor 2 (VEGFR2), or downstream STAT3, would inhibit VEGF-induced retinopathy without delaying physiologic retinal vascular development.
|
29730824 |
2018 |
|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Transcription factors regulate GPR91-mediated expression of VEGF in hypoxia-induced retinopathy.
|
28374767 |
2017 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
This study suggests that melatonin may have potential value in the prevention and treatment of various retinal diseases associated with increase of VEGF, vascular leakage and angiogenesis.
|
27409056 |
2017 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The newly developed anti-Tspan12 antibody has therapeutic effects in vasoproliferative retinopathy and can enhance the potency of existing anti- vascular endothelial growth factor agents.
|
28356444 |
2017 |
|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
CCR7 and VEGF mRNA were expressed at higher levels in the OIR and OIR control groups than in the normoxia and OIR treated groups.
|
28730075 |
2017 |
|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We hypothesised that the initial reduction of central macular thickness by ranibizumab should be maximum in severe diabetic retinopathy until the levels of VEGF decreases to the levels observed in eyes with mild retinopathy.MethodsConsecutive patients with centre-involving DMO (central subfield thickness (CSFT)>300 μm) who had three consecutive monthly ranibizumab injections followed by as needed therapy were included.
|
28452992 |
2017 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
AXT107 reduced the VEGF-induced vascular leakage that underlies macular edema in ischemic retinopathies and NVAMD.
|
28100839 |
2017 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Galectin-1 expression imprints a neurovascular phenotype in proliferative retinopathies and delineates responses to anti-VEGF.
|
28455954 |
2017 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
These data explain the broad range of benefits obtained by VEGF suppression in patients with ischemic retinopathies, provide an important insight into the pathogenesis of RVO and diabetic retinopathy, and suggest that sustained suppression of VEGF early in the course of these diseases may prevent vessel closure, worsening ischemia, and disease progression.
|
28931763 |
2017 |